APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Age-Related Macular Degeneration (AMD) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Age-Related Macular Degeneration (AMD) Therapeutics Market Outlook and Growth Opportunities 2026

Report ID 173961270422 December 2025197 pages

Choose your research edition.

Industry ResearchAge-Related Macular Degeneration (AMD) Therapeutics Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Age-Related Macular Degeneration (AMD) Therapeutics Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Age-Related Macular Degeneration (AMD) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Age-Related Macular Degeneration (AMD) Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Age-Related Macular Degeneration (AMD) Therapeutics Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Age-Related Macular Degeneration (AMD) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Age-Related Macular Degeneration (AMD) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Age-Related Macular Degeneration (AMD) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Age-Related Macular Degeneration (AMD) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Age-Related Macular Degeneration (AMD) Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Age-Related Macular Degeneration (AMD) Therapeutics market include Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd. and Bausch Health Companies, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Age-Related Macular Degeneration (AMD) Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Age-Related Macular Degeneration (AMD) Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Age-Related Macular Degeneration (AMD) Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Age-Related Macular Degeneration (AMD) Therapeutics market.

Age-Related Macular Degeneration (AMD) Therapeutics Segment by Company

Novartis AG

Amgen Inc.

Regeneron Pharmaceuticals Inc.

F. Hoffmann-La Roche Ltd.

Bausch Health Companies, Inc.

Age-Related Macular Degeneration (AMD) Therapeutics Segment by Type

Wet AMD

Dry AMD

Age-Related Macular Degeneration (AMD) Therapeutics Segment by Application

Clinic

Hospital

Research Institute

Other

Age-Related Macular Degeneration (AMD) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Age-Related Macular Degeneration (AMD) Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Age-Related Macular Degeneration (AMD) Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Age-Related Macular Degeneration (AMD) Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Age-Related Macular Degeneration (AMD) Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Age-Related Macular Degeneration (AMD) Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Age-Related Macular Degeneration (AMD) Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Age-Related Macular Degeneration (AMD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Age-Related Macular Degeneration (AMD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Age-Related Macular Degeneration (AMD) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Age-Related Macular Degeneration (AMD) Therapeutics industry.

Chapter 3: Detailed analysis of Age-Related Macular Degeneration (AMD) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Age-Related Macular Degeneration (AMD) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Age-Related Macular Degeneration (AMD) Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Age-Related Macular Degeneration (AMD) Therapeutics Industry Trends Table 2. Age-Related Macular Degeneration (AMD) Therapeutics Industry Drivers Table 3. Age-Related Macular Degeneration (AMD) Therapeutics Industry Opportunities and Challenges Table 4. Age-Related Macular Degeneration (AMD) Therapeutics Industry Restraints Table 5. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Age-Related Macular Degeneration (AMD) Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Age-Related Macular Degeneration (AMD) Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Age-Related Macular Degeneration (AMD) Therapeutics Company, Product Type & Application Table 10. Global Age-Related Macular Degeneration (AMD) Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Age-Related Macular Degeneration (AMD) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Wet AMD Table 15. Significant Companies of Dry AMD Table 16. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type (2021-2026) Table 20. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Clinic Table 22. Significant Companies of Hospital Table 23. Significant Companies of Research Institute Table 24. Significant Companies of Other Table 25. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application (2021-2026) Table 29. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application (2027-2032) Table 30. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Region (2021-2026) Table 33. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Region (2027-2032) Table 35. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Market Share by Country (2021-2026) Table 38. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Market Share by Country (2027-2032) Table 40. Novartis AG Company Information Table 41. Novartis AG Business Overview Table 42. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio Table 44. Novartis AG Recent Development Table 45. Amgen Inc. Company Information Table 46. Amgen Inc. Business Overview Table 47. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio Table 49. Amgen Inc. Recent Development Table 50. Regeneron Pharmaceuticals Inc. Company Information Table 51. Regeneron Pharmaceuticals Inc. Business Overview Table 52. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio Table 54. Regeneron Pharmaceuticals Inc. Recent Development Table 55. F. Hoffmann-La Roche Ltd. Company Information Table 56. F. Hoffmann-La Roche Ltd. Business Overview Table 57. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio Table 59. F. Hoffmann-La Roche Ltd. Recent Development Table 60. Bausch Health Companies, Inc. Company Information Table 61. Bausch Health Companies, Inc. Business Overview Table 62. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio Table 64. Bausch Health Companies, Inc. Recent Development Table 65. Research Programs/Design for This Report Table 66. Authors List of This Report Table 67. Secondary Sources Table 68. Primary Sources List of Figures Figure 1. Age-Related Macular Degeneration (AMD) Therapeutics Product Image Figure 2. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Age-Related Macular Degeneration (AMD) Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Wet AMD Image Figure 8. Dry AMD Image Figure 9. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type (2021-2032) Figure 12. Clinic Image Figure 13. Hospital Image Figure 14. Research Institute Image Figure 15. Other Image Figure 16. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application (2021-2032) Figure 19. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Age-Related Macular Degeneration (AMD) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 22. North America Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Age-Related Macular Degeneration (AMD) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Age-Related Macular Degeneration (AMD) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. South America Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Wet AMD
  • Dry AMD
Applications
  • Clinic
  • Hospital
  • Research Institute
  • Other
Companies covered
  • Novartis AG
  • Amgen Inc.
  • Regeneron Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bausch Health Companies, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Age-Related Macular Degeneration (AMD) Therapeutics Market Dynamics
  1. 2.1 Age-Related Macular Degeneration (AMD) Therapeutics Industry Trends
  2. 2.2 Age-Related Macular Degeneration (AMD) Therapeutics Industry Drivers
  3. 2.3 Age-Related Macular Degeneration (AMD) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Age-Related Macular Degeneration (AMD) Therapeutics Industry Restraints
3 Age-Related Macular Degeneration (AMD) Therapeutics Market by Company
  1. 3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Age-Related Macular Degeneration (AMD) Therapeutics Company Product Type and Application
  6. 3.6 Global Age-Related Macular Degeneration (AMD) Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Age-Related Macular Degeneration (AMD) Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Age-Related Macular Degeneration (AMD) Therapeutics Market by Type
  1. 4.1 Age-Related Macular Degeneration (AMD) Therapeutics Type Introduction
  2. 4.1.1 Wet AMD
  3. 4.1.2 Dry AMD
  4. 4.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Type
  5. 4.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Type (2021-2032)
  7. 4.2.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type (2021-2032)
5 Age-Related Macular Degeneration (AMD) Therapeutics Market by Application
  1. 5.1 Age-Related Macular Degeneration (AMD) Therapeutics Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Research Institute
  5. 5.1.4 Other
  6. 5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Application
  7. 5.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Application (2021-2032)
  9. 5.2.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application (2021-2032)
6 Age-Related Macular Degeneration (AMD) Therapeutics Regional Value Analysis
  1. 6.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Age-Related Macular Degeneration (AMD) Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Age-Related Macular Degeneration (AMD) Therapeutics Country-level Value Analysis
  1. 7.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Amgen Inc.
  8. 8.2.1 Amgen Inc. Company Information
  9. 8.2.2 Amgen Inc. Business Overview
  10. 8.2.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
  12. 8.2.5 Amgen Inc. Recent Developments
  13. 8.3 Regeneron Pharmaceuticals Inc.
  14. 8.3.1 Regeneron Pharmaceuticals Inc. Company Information
  15. 8.3.2 Regeneron Pharmaceuticals Inc. Business Overview
  16. 8.3.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
  18. 8.3.5 Regeneron Pharmaceuticals Inc. Recent Developments
  19. 8.4 F. Hoffmann-La Roche Ltd.
  20. 8.4.1 F. Hoffmann-La Roche Ltd. Company Information
  21. 8.4.2 F. Hoffmann-La Roche Ltd. Business Overview
  22. 8.4.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
  24. 8.4.5 F. Hoffmann-La Roche Ltd. Recent Developments
  25. 8.5 Bausch Health Companies, Inc.
  26. 8.5.1 Bausch Health Companies, Inc. Company Information
  27. 8.5.2 Bausch Health Companies, Inc. Business Overview
  28. 8.5.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
  30. 8.5.5 Bausch Health Companies, Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst